FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Drug Information Updates
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Drug Information Updates
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
Pinpointing the Top Questions about Biosimilars in Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology
CME/CE
Pinpointing the Top Questions about Biosimilars in Rheumatology
- Leonard H. Calabrese, DO
- John R. Tesser, MD